Transbronchial Needle Aspiration Biopsy Research Articles

Transbronchial lymph node forceps biopsy as a novel tool in diagnosis of mediastinal lymphadenopathy: a pilot study

BackgroundDifferential diagnosis of mediastinal lymphadenopathy is an issue of debate. Lymph nodes may be enlarged due to a variety of inflammatory, infectious, or malignant reasons. Therefore, obtaining samples from the affected nodes is crucial for the diagnosis. Usually, these patients are subjected to TBNA (EBUS or conventional) or mediastinoscopy if TBNA is not conclusive. This study evaluated the safety and feasibility of this new technique of transbronchial forceps biopsy for the diagnosis of mediastinal lymphadenopathy.MethodsThe study included 18 patients with confirmed mediastinal lymphadenopathy who were admitted in Chest Department, Cairo University in the period from December 2019 to December 2020. All patients were subjected to flexible bronchoscopy with conventional transbronchial needle aspiration (C-TBNA) and transbronchial forceps biopsy (LN-TBFB) from the enlarged mediastinal lymph node in the same procedure.Resultswe found the technique of LN-TBFB safe with no serious complications. We were able to reach a diagnosis in 7/7 (100%) cases of sarcoidosis, 6/7 (85.7%) cases of malignant lymph nodes. We had three cases where the histopathology showed hyperactive follicular hyperplasia, and a single case of tuberculous lymphadenitis. C-TBNA was diagnostic in 71.4% of sarcoidosis cases, 42.9% of malignant cases, but failed to diagnose the one patient with tuberculous lymphadenitis.ConclusionLymph node transbronchial forceps biopsy (LN-TBFB) was found to be safe and effective in the diagnosis of mediastinal lymphadenopathy. We strongly advocate the use of this minimally invasive technique for diagnosing pathologically enlarged mediastinal lymph nodes, as a last step before mediastinoscopy.

Utility of Narrow-band Imaging Bronchoscopy in the Diagnosis of Endobronchial Sarcoidosis.

There are few reports on the utility of bronchoscopic narrow-band imaging (NBI) for visualizing endobronchial abnormalities in sarcoidosis. Our primary objective was to compare the sensitivity of finding endobronchial abnormality using NBI versus white light bronchoscopy (WLB) in patients with sarcoidosis. The secondary aim was to evaluate the sensitivity of NBI in diagnosing endobronchial sarcoidosis against a reference standard of positive endobronchial biopsy (EBB). We retrospectively included subjects with sarcoidosis, where we sequentially recorded WLB and NBI videos to visualize the endobronchial mucosa. We collected data on the demographic findings, sarcoidosis stage, and the histopathological findings of transbronchial needle aspiration, EBB, and transbronchial lung biopsy. Three experienced bronchoscopists viewed the video recordings and noted the abnormalities of the airway mucosa separately on WLB and NBI. We included 28 subjects (mean age, 42.9y; 53.6% men; 14 each, stages 1 and 2) with a final diagnosis of sarcoidosis. Granulomas were detected on EBB in 11 (39.3%) subjects. We identified endobronchial nodules in 10 and 15 subjects on WLB and NBI. The sensitivity of finding endobronchial abnormality using WLB and NBI was 35.7% (10/28) and 53.6% (15/28), respectively (χ2=1.77, df=1, P=0.18). The sensitivity of NBI in diagnosing endobronchial sarcoidosis against a positive EBB was 63.6% (7/11 subjects). There was excellent agreement (Κ=0.86) for detecting nodules on NBI among the 3 observers. NBI might allow the identification of additional abnormalities not detected on WLB in sarcoidosis. Larger studies are required to confirm our observations.

Clinical application of endobronchial ultrasonography-guided transbronchial needle aspiration biopsy—a single center, large sample, real-world study

BackgroundEndobronchial ultrasonography-guided transbronchial needle aspiration biopsy (EBUS-TBNA) has been used for more than 10 years in China. Its clinical application and diagnostic value in different diseases with large sample was lack of report.MethodsA retrospective analysis was performed about the application and diagnostic value of EBUS-TBNA in different disease of patients in Respiratory Intervention Center of Guangzhou Institute of Respiratory Health from January 2012 to July 2020.ResultsA total 5758 patients were included with 182 patients excluded for lack of information. Finally, data of 5576 patients (3798 males and 1778 females) were analyzed. For anesthetize, most patients were undergoing general anesthesia of intravenous with spontaneous breathing (69.4%), followed by general anesthesia of intravenous and inhalation with tracheal intubation and mechanical ventilation (17.9%) and conscious sedation and analgesia (12.8%). Lymph nodes were the main sites of biopsy obtained (76.4%). Tumors accounted for the highest proportion of disease (66.4%), followed by infection diseases (9.9%), sarcoidosis (3.9%), lymphoma (1.1%), and others (18.7%). The sensitivity of EBUS-TBNA for diagnosis of tumor was 89.7%, and 40.8% for infection diseases. There were significant differences in the puncture site and proportions of diseases between male and females (both p < 0.05). Higher diagnostic value was found in male patients (p < 0.05).ConclusionEBUS-TBNA has good diagnostic value for different mediastinal and central pulmonary space-occupying lesions diseases, with highest sensitivity for tumors. Higher diagnostic value was found in male patients.

Utility of multimodal sampling and testing during advanced bronchoscopy for diagnosing atypical respiratory infections in a Coccidioides-endemic region.

The role of advanced diagnostic bronchoscopy (ADB) for assessing atypical respiratory infections is unclear. The purpose of this study was to ascertain: (I) the diagnostic utility of ADB-tissue sampling in patients with focal thoracic lesions due to atypical respiratory infections; (II) how multimodal bronchoscopic sampling and testing enhance diagnosis in a Coccidioides-endemic region. A retrospective observational cohort study analyzing all ADBs performed over a 10-year period in patients with focal thoracic lesions diagnosed with a non-malignant disorder. Only cases which procured lower respiratory tract secretion and tissue samples by ADB, and had both cytohistology and culture results available were included. Among 403 subjects with non-malignant disease, 136 (33.7%) were diagnosed with atypical respiratory infections, with ADB contributing a diagnosis in 119 (87.5%) of these. Coccidioidal disease was independently associated with a cytohistologic diagnosis [odds ratio =7.64, 95% confidence interval (CI): 2.51-23.26; P<0.001]. Mycobacteria were more effectively identified by culture (overall yield of 8.4%, vs. 2.7% by cytohistology; P<0.001). Among subjects for which both respiratory secretion and tissue sampling were dual-tested with culture and cytology/cytohistology, adding ADB-guided transbronchial needle aspiration and/or forceps biopsy (TBNA/TBFB) to bronchoalveolar lavage and/or bronchial washings (BAL/BW) more than doubled the yield for dimorphic fungi, from 7.1% to 15.1% (increase of 8.0%, 95% CI: 5.2-11.9%). For lung lesions, adding tissue culture to dual TBNA/TBFB cytohistology-tested lung samples doubled the proportion diagnosed with atypical infection over using TBNA-cytohistology alone (increase of 15.8%, 95% CI: 10.4-23.1%). Adding lymph node to lung sampling increased the proportion diagnosed with coccidioidomycosis by 8.8% (95% CI: 4.8-15%). Among subjects with atypical respiratory infections, major ADB-related complications occurred in 1.5%. ADB is useful for diagnosing atypical respiratory infections manifesting as focal thoracic lesions. A multimodal approach to both sampling and testing enhances yield, while maintaining a favorable procedure safety profile. Cytohistology testing and nodal sampling are beneficial for pulmonary coccidioidomycosis, and culture for mycobacterial disease. The approach to ADB-sampling should be adjusted according to clinical context and regional infection patterns.

Evaluation of hypermetabolic mediastinal-hilar lymph nodes determined by PET/CT with EBUS-TBNA and calculation of SUVmax cutoff values in differentiation of malignancy.

Computed tomography (CT) and positron emission tomography (PET) are the most commonly used methods for diagnosis and staging in both malignant and benign diseases of the lung parenchyma and mediastinum. Endobronchial ultrasonography (EBUS) guided transbronchial needle aspiration biopsy (TBNA) has become widespread in recent years because it allows minimally invasive tissue sampling. PET-CT has high sensitivity in the diagnosis of malignancy but has low specificity. The false positive rate is high with the SUVmax 2.5 cutoff value, which is widely used in studies about malignancy. In our study, we evaluated lymph nodes with high F18-fluorodeoxyglucose (FDG) uptake on PET/CT and sampled by EBUS-TBNA. We aimed to calculate the new SUVmax cutoff values in the differentiation of malignancy. Our study included 103 patients who were examined for any reason and who underwent biopsy with EBUS-TBNA due to mediastinal or hilar lymph node enlargement on PET-CT. The relationship between PET-CT findings and EBUS findings, EBUS-TBNA results was evaluated. Biopsies were taken from 140 lymph nodes in 103 patients included in our study, and 39 (27.8%) were diagnosed as malignant. In our study, when the SUVmax cutoff value in PET-CT is taken as 2.54, the sensitivity is 98%, but the specificity remains at the level of 12%. When the SUVmax cutoff value in PET-CT was taken as 4.58, the sensitivity was 92% and the specificity was 49%. When this value was accepted as 5.25, and 6.09 the sensitivity was respectively 90% and 85%, the specificity was respectively 52% and 60%. In evaluations, we conducted in order to determine different SUVmax cutoff values that can be used for higher sensitivity and specificity in malignancy studies, the cutoff values were 4.58, 5.25, and 6.09. It is thought that these cutoff values will be useful both for diagnosing malignancy and for distinguishing benign pathologies.

Comparative Analysis of Results of Transbronchial Needle Aspiration Biopsy of Mediastinal Lymph Nodes with Flexible and Rigid Tracheobronchoscopy for Verification of Mediastinal Lymphadenopathies

Comparative Analysis of Results of Transbronchial Needle Aspiration Biopsy of Mediastinal Lymph Nodes with Flexible and Rigid Tracheobronchoscopy for Verification of Mediastinal Lymphadenopathies

Endobronchial spread of tuberculosis after endobronchial ultrasound-guided transbronchial needle aspiration and intranodal forceps biopsy.

Endobronchial spread of tuberculosis after endobronchial ultrasound-guided transbronchial needle aspiration and intranodal forceps biopsy.

Efficacy of TBNA needles for EBUS during fiberoptic bronchoscopy?

Conventional transbronchial needle aspiration (cTBNA) biopsy is a diagnostic minimally invasive technique applied using fibreoptic bronchoscopy (FOB) in the evaluation of mediastinal/hilar lymph nodes. With the development of endobronchial ultrasound (EBUS) devices, transbronchial aspiration needles have been revised for use according to the EBUS guidelines. The main aim of this research was to evaluate the diagnostic success of transbronchial aspiration needles that was produced for EBUS when it was applied with FOB instead of conventional TBNA. A retrospective examination was made with the data of 35 patients applied with FOB TBNA, using needles specifically designed for EBUS and 36 patients with conventional TBNA (cTBNA group), for lung cancer staging or the diagnosis of mediastinal lymphadenopathy between November 2018 and November 2019. Seventy-two and sixty procedures performed on 71 patients were included in the study. Diagnostic efficiency for TBNA and cTBNA groups were 91.4% and 83.3%, respectively. Conventional TBNA is still acceptable when the low cost and ease of application are taken into consideration. In conclusion, improvement of current conventional TBNA needles similar to EBUS-TBNA needles for more efficient aspiration capacity could be the first stepto increasing the TBNA diagnostic yield. Nevertheless, further studies are needed to confirm our results.

Rotation aiding technique for endobronchial ultrasound-guided transbronchial needle aspiration biopsy of intrathoracic lymph nodes: A complementary approach to the conventional jabbing method.

BackgroundThis study aimed to compare the lymph node core tissue lengths obtained via mediastinal or hilar lymphadenopathy using the complementary “rotation aiding” and conventional Jab technique.MethodsWe prospectively measured the lymph node core tissue length in patients who sequentially underwent the Jab and rotation aiding (RA) techniques between October 2012 and December 2014. Wilcoxon signed‐rank test was used to compare the core tissue length and grade of diagnostic cells obtained by each technique. McNemar's test was used to compare the proportion of adequate cellularity (≥grade 2) between the aspiration techniques.ResultsThe core tissue length of 61 lymph nodes from 43 patients (mean age: 63 years, range: 16–86 years) was analyzed. Pathological findings were consistent with malignant lesions in 25 (41%) patients and benign lesions in 36 (59%). The most common diagnosis in benign lymph nodes was reactive, followed by tuberculosis and sarcoidosis. We obtained longer core tissue with RA technique than with the Jab technique (83.2 ± 12.7 vs. 60.1 ± 10.1 mm; p = 0.02). There was a significant increase in cellularity grade and proportion of ≥grade 2 cells with the RA technique than with the Jab technique (2.39 ± 1.08 vs. 1.84 ± 1.14; p < 0.001, 78.7% vs. 52.5%; p = 0.002), regardless of the pathological diagnosis.ConclusionsRA technique facilitated more lymph node samples in terms of core tissue length and cellularity than the Jab technique.

INIITIAL EXPERIENCE WITH STEERABLE INSTRUMENTATION IN HUMAN CADAVERIC MODELS WITH SIMULATED TUMOR TARGETS

TOPIC: Procedures TYPE: Original Investigations PURPOSE: Despite growing experience using advanced guided techniques, the diagnostic yield of bronchoscopy for peripheral pulmonary lesions remains suboptimal, particularly for lesions which are adjacent to peripheral bronchi. While recent publications have focused on improving bronchoscopic reach, access and precision in the lung periphery, few have addressed significant modifications to the instrumentation used to obtain biopsies. This exercise was performed to evaluate two novel, steerable instruments within human cadaveric lungs with simulated tumor targets. Instrument assessment included the ability of both instruments to access simulated tumor targets in all lobes of the lung, as well as to reposition instruments within tumor targets. METHODS: Artificial tumor targets were placed in all lobes of the lungs of two human cadaver torsos which were intubated, ventilated and underwent CT scanning. Bronchoscopists utilized a large caliber bronchoscope (BF-1TH190, Olympus, Tokyo, Japan) and steerable guide sheath (2.7mm OD)(SerpeX Medical, Santa Clara, CA) by advancing, rotating and articulating the distal end of the guide sheath towards the targeted lesion using fluoroscopic guidance and a reference CT scan. Radial probe endobronchial ultrasound (UM S20-17S, Olympus Tokyo, Japan) was used to confirm lesion localization prior to performing transbronchial needle aspiration (Periview Flex, Olympus, Tokyo, Japan) and transbronchial biopsy (Precisor Broncho Forceps, ConMed, Utica, NY). Following this, a standard diagnostic bronchoscope (BF-H190, Olympus, Tokyo, Japan) was used to advance a steerable needle (1.8mm OD)(SerpeX Medical, Santa Clara, CA) towards the same targeted lesions using insertion, rotation and articulation of the distal tip. RESULTS: Both the steerable sheath and steerable needle were successfully placed within simulated tumor targets in all lobes of two cadaveric lungs with diagnostic biopsy material obtained from all lobes. Additionally, manipulation of the distal end of the steerable sheath and steerable needle was successfully used to reposition each tool within different locations of the same lesion. CONCLUSIONS: This is an initial reporting of two fully articulating, steerable instruments designed to assist with bronchoscopic biopsy of peripheral lung lesions. In this exercise both instruments were successfully positioned within tumor targets in all lobes of two human cadaveric lungs. Additionally, articulation and rotation of the distal end of each of these instruments successfully repositioned biopsy instruments within different locations of targeted lesions. CLINICAL IMPLICATIONS: Steerable instrumentation may improve the bronchoscopist's ability to place biopsy tools within targeted peripheral lesions, thereby potentially improving diagnostic yield, particularly for lesions that are positioned adjacent to peripheral bronchi. DISCLOSURES: Consultant relationship with Serpex Please note: 2020-2021 Added 04/24/2021 by Alexander Chen, source=Web Response, value=Consulting fee Removed 04/27/2021 by Alexander Chen, source=Web Response Investigator relationship with Olympus Please note: 2020-2021 Added 04/27/2021 by Alexander Chen, source=Web Response, value=Grant/Research Support Consultant relationship with Boston Scientific Please note: 2020-2021 Added 05/10/2021 by Alexander Chen, source=Web Response, value=Consulting fee Consultant relationship with Olympus America, Inc Please note: 1/2019 to current Added 04/28/2021 by Andrew Haas, source=Web Response, value=Consulting fee Consultant relationship with Serpex Medical Please note: 1/2020 to current Added 04/28/2021 by Andrew Haas, source=Web Response, value=Consulting fee DSMB, consultant relationship with Novocure, Inc Please note: 1/2019 to current Added 04/28/2021 by Andrew Haas, source=Web Response, value=Consulting fee Consultant relationship with Olympus America Please note: 1/2019 to current Added 04/28/2021 by Andrew Haas, source=Web Response, value=Consulting fee No relevant relationships by Michael Machuzak, source=Web Response

4D Electromagnetic Navigation Bronchoscopy for the Sampling of Pulmonary Lesions: First European Real-Life Experience

PurposeThe use of Electromagnetic navigation bronchoscopy (ENB) for the diagnosis of pulmonary peripheral lesions is still debated due to its variable diagnostic yield; a new 4D ENB system, acquiring inspiratory and expiratory computed tomography (CT) scans, overcomes respiratory motion and uses tracked sampling instruments, reaching higher diagnostic yields. We aimed at evaluating diagnostic yield and accuracy of a 4D ENB system in sampling pulmonary lesions and at describing their influencing factors.MethodsWe conducted a three-year retrospective observational study including all patients with pulmonary lesions who underwent 4D ENB with diagnostic purposes; all the factors potentially influencing diagnosis were recorded.Results103 ENB procedures were included; diagnostic yield and accuracy were, respectively, 55.3% and 66.3%. We reported a navigation success rate of 80.6% and a diagnosis with ENB was achieved in 68.3% of cases; sensitivity for malignancy was 61.8%. The majority of lesions had a bronchus sign on CT, but only the size of lesions influenced ENB diagnosis (p < 0.05). Transbronchial needle aspiration biopsy was the most used tool (93.2% of times) with the higher diagnostic rate (70.2%). We reported only one case of pneumothorax.ConclusionThe diagnostic performance of a 4D ENB system is lower than other previous navigation systems used in research settings. Several factors still influence the reachability of the lesion and therefore diagnostic yield. Patient selection, as well as the multimodality approach of the lesion, is strongly recommended to obtain higher diagnostic yield and accuracy, with a low rate of complications.

First case of lung cancer with pneumoconiosis and endobronchial leiomyoma complicating the diagnosis

BackgroundIn the treatment of lung cancer, the presence or absence of mediastinal lymph node involvement has a significant bearing on the indication for surgery. In addition, if a tumor is found in the trachea during preoperative scrutiny of lung cancer, the possibility of intratracheal metastasis should be considered, since this kind of metastasis is a contraindication for surgery. In the present study, we experienced a case of lung cancer associated with pneumoconiosis and a rare intratracheal leiomyoma. In this case, preoperative staging was difficult, but endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and intratracheal tumor biopsy were helpful in determining the treatment strategy.Case presentationA 65-year-old man was referred to our hospital for evaluation of abnormal chest X-ray shadows. Sputum cytology indicated squamous cell carcinoma. PET-CT scan showed fluorodeoxyglucose uptake in a right upper lobe mass and the hilar, mediastinal and right supraclavicular lymph nodes, and bronchoscopy revealed a protuberant lesion in the left bronchus. Hence, EBUS-TBNA for the mediastinal lymph nodes and simultaneous evaluation of the protuberant lesion in the left bronchus were performed. The bronchial tumor was histopathologically diagnosed as leiomyoma. Since mediastinal lymph node biopsy showed no malignant cells, a right upper lobectomy and a right S6 segmentectomy were performed. Postoperative pathological evaluation of the dissected lymph nodes revealed pneumoconiosis but no metastasis. He was, thus, diagnosed with squamous cell lung carcinoma (pT2bN0M0, pStage IIA).ConclusionsWe report a patient with lung cancer and coexistence of a rare endobronchial leiomyoma and pneumoconiosis, who underwent surgery after preoperative evaluation using EBUS-TBNA.

Suitability of endobronchial ultrasound-guided transbronchial needle aspiration samples for programmed death ligand-1 testing in non-small cell lung cancer, the Bristol experience.

Treatment for non-small cell lung cancer (NSCLC) is now personalised using molecular mutation testing. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsy suitability for anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) mutation testing is established. Less is currently known about EBUS-TBNA suitability for PD-L1 (programmed death ligand-1) testing. To assess EBUS-TBNA biopsy adequacy for ALK, EGFR and PD-L1 testing, we conducted a prospective study of 279 consecutive NSCLC patients referred to a tertiary EBUS-TBNA centre in South West England. One hundred eight-four (62.6%) patients were found to have adenocarcinoma, 83 (28.2%) had squamous cell carcinoma, and 27 (9.2%) were identified as NSCLC-not otherwise specified. EGFR testing was successful in 166 of 168 patients (98.8%), ALK testing in all 115 and PD-L1 testing in 43 of 49 patients (88.2%). Previous EGFR and ALK testing did not affect biopsy PD-L1 testing success. PD-L1 testing failures occurred in three of five (60.0%) of 22G needle biopsies, one of five (20.0%) of 21G needle biopsies and two of 39 (5.1%) of 19G needle biopsies, P=.016. EBUS-TBNA biopsies are mostly suitable for PD-L1 testing. Larger needle size may improve PD-L1 (but not EGFR and ALK) testing success but requires further study in a controlled trial.

Lesion characteristics affecting yield of electromagnetic navigational bronchoscopy.

Electromagnetic navigational bronchoscopy (ENB) is an important, minimally invasive diagnostic tool for malignant and benign peripheral lung lesions, offering lower complication risks than transthoracic needle aspirations. As a relatively new technology, the best sampling modality and lesion characteristics for ENB has yet to be determined. We evaluated the sensitivity and diagnostic yield of different sampling modalities (needle aspiration, brush biopsy, transbronchial forceps biopsies) and radiographical lesion characteristics by Tsuboi classification. We also evaluated the difference in yield and sensitivity with the addition of radial probe EBUS to augment ENB. We completed a retrospective chart review of all patients that had ENB performed at our institution since its implementation in 2011. We reviewed the lesion size, location, Tsuboi classification, cytology, pathology results and analyzed biopsy specimen tool types. We included a total of 248 patients who had ENB performed between 2011 and 2018. Average age was 67 years and 50% female. A total of 270 lesions were targeted with a mean size of 24±12mm. Sensitivity for malignancy was 59.2% with a diagnostic yield of 72.3%. Sensitivity and diagnostic accuracy trended higher with combined sampling modalities (brush and transbronchial needle aspiration and forcep biopsy). Lesions with type I and type II Tsuboi classification of bronchus sign had higher sensitivity compared to type III classification (67.9% [n=101 type I], 64.6% [n=65 type II], 37.9% [n=36 type III]), p=0.01 and p=0.04. For navigation bronchoscopy, sensitivity is higher in bronchus sign lesions that end directly into lesion (Tsuboi type I) and travel through malignant lesions (Tsuboi type II) compared to tangentially circumventing the lesion (Tsuboi type III).

Endobronchial and/or Endoesophageal Bronchoscopic Ultrasound-Guided Fine Needle Aspiration in the Diagnosis of Mediastinal and Hilar Diseases of Unknown Etiologies

<i>Introduction:</i> Diagnosis of mediastinal and hilar lesions represents a problematic issue for long ago, not only due to various structures that occupy this space but also difficult accessibility to such lesions. Mediastinal endosonography – guided FNA is emerged as a new minimally invasive modality for diagnosis of such lesions. <i>Objectives: </i>to evaluate the role of endobronchial and/ or endoesophageal -bronchoscopic ultrasound-guided fine needle aspiration in the diagnosis of mediastinal and hilar diseases of unknown etiologies. <i>Methods:</i> This Prospective observational study was carried out at Tanta University Educational Hospital and Kobri Elkobba Military Hospitals; from December 2017 to December 2019 on thirty patients (19 males; 11 females, age range 17-82 years) presented with undiagnosed mediastinal and or hilar lesions. All patients were subjected to clinical examination, radiological assessment including Chest-X-Ray, CT Chest. Laboratory investigations: CBC, blood urea, serum creatinine and coagulation profile. Twenty-six patients were subjected only to endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsies and four patients were subjected to endoscopic ultrasound using EBUS scope-guided fine- needle aspiration (EUS-B-FNA) after EBUS-TBNA, using Pentax Endobronchial ultrasound and a fine needle (22- Gauge). The procedure was done under local anesthesia and conscious sedation ROSE technique was applied for some cases. <i>Results:</i> Definitive diagnosis was reached in twenty-nine cases, achieving diagnostic yield (96.67%). Malignant lesions were the predominant category; twenty (66.67%), while nine (30%) were diagnosed as benign lesions and one (3.33%) case remained un diagnosed. Also, immunohistochemistry played an important role to reach definitive diagnosis in six cases without further sampling. About (12/30; 40%) of patients were passed without any complications while the others recorded controlled complications without any serious events. <i>Conclusion: </i>EBUS and EUS-B-FNA are minimally invasive, complementary and cost effective procedures with high diagnostic yield for mediastinal and hilar lesions. Addition of immunohistochemistry raises diagnostic value of this procedure.

A case of Takotsubo cardiomyopathy after bronchoscopy

Takotsubo Cardiomyopathy (TCM), also known as Broken Heart Syndrome, is an acute stress-induced cardiomyopathy with transient cardiac failure. It is triggered by preceding extreme physical or psychological stress. The etiology remains unclear, however, pathophysiological activation of the adrenergic system causing catecholamine-induced myocardial dysfunction is proposed. Use/ overuse of short acting beta-2-agonist (SABA) is a possible predisposing factor. We report a case of TCM in a 64-year-old female after bronchoscopy with endobronchial ultrasound (EBUS) and transbronchial needle aspiration biopsy (TNAB). The case shows a possible delay from symptom onset to echocardiographic visibility of TCM on and underlines the importance of reviewing a patient’s use of SABA prior to invasive procedures.

COMPARISON OF DIAGNOSTIC YIELD OF ELECTROMAGNETIC NAVIGATION BRONCHOSCOPY-GUIDED TRANSBRONCHIAL FORCEPS BIOPSY TO TRANSBRONCHIAL NEEDLE ASPIRATION IN THE DIAGNOSIS OF PERIPHERAL PULMONARY LESIONS

SESSION TITLE: Procedures Posters SESSION TYPE: Original Investigation Posters PRESENTED ON: October 18-21, 2020 PURPOSE: The use of electromagnetic navigation as an adjunct to flexible bronchoscopy in the diagnosis of pulmonary lesions has been shown to improve yield. In this study, we compared the diagnostic yield of concurrently performed transbronchial needle aspiration (TBNA) and transbronchial forceps biopsy (TBFB) in patients undergoing electromagnetic navigation-guided bronchoscopy (ENB) for diagnosis of peripheral pulmonary lesions. METHODS: A retrospective study was conducted on all patients who underwent concurrent ENB-guided transbronchial needle aspirations and transbronchial forceps biopsies at Ochsner LSU Health Shreveport, LA between July 2018 to December 2019. RESULTS: 86 ENB procedures were performed on 82 patients (mean age 62 years; 35 females, 47 males); four patients needed repeat procedures for new pulmonary lesions or for prior negative studies. 72 (88%) patients had a history of nicotine use and 37 (45%) had a history of malignancy. Of 86 procedures done, samples were inadequate or non-diagnostic in 6 cases, while 9 cases were lost to follow up, and as such final diagnoses of the lung lesions could not be confirmed. Of the remaining 71 procedures, ENB was diagnostic in 53 cases (75%; 42 malignant, 11 non-malignant) and was falsely negative in 18 cases (25%; 16 malignant and 2 non-malignant). False negatives were diagnosed with CT-guided biopsy or at lobectomy. Overall, the sensitivity of concurrent ENB-guided TBNA with TBFB in the diagnosis of malignant and benign peripheral pulmonary lesions was 72% (p = 0.03). Of 58 total malignant cases, transbronchial needle aspiration (TBNA) positively compared to transbronchial forceps biopsy (TBFB) with 39/58 vs 32/58 (sensitivity 67.2% vs 55.2%; p = 0.0001). Sensitivity for diagnosis of malignant lesions increased to 72.4% (P < 0.0001) when both methods were combined. Of the 13 nonmalignant cases, TBFB gave a definite diagnosis in 10/13 vs 8/13 for TBNA (sensitivity 60% vs 30%; p = > 0.05). Using both methods, sensitivity increased to 70% (p = 0.0699). There were no significant complications. The average follow up period was from 3 months to 2 years; patients followed up for less than 6 months showed improvement or resolution of symptoms and or image findings on follow up. CONCLUSIONS: While TBNA alone appeared to have a better performance than TBFB alone in the diagnosis of malignant pulmonary lesions during ENB, the combination of both methods significantly increased diagnostic yield for both malignant and non-malignant lesions. Thus, more widespread use of both instruments during ENB, and even during simple endobronchial bronchoscopies, could increase the sensitivities of both procedures. CLINICAL IMPLICATIONS: To the best our knowledge, this is the first study comparing diagnostic yield of concurrently performed transbronchial needle aspiration (TBNA) and transbronchial forceps biopsy (TBFB) at electromagnetic navigation guided bronchoscopy. DISCLOSURES: No relevant relationships by Olaedo Abana, source=Web Response No relevant relationships by UZAIR Ghori, source=Web Response Site Investigator for EMPROVE relationship with Olympus-Spiration Please note: $1001 - $5000 Added 06/15/2020 by Robert Holladay, source=Web Response, value=Grant/Research Support Site Investigator for DAS 181 relationship with Ansun pharmaceutical Please note: $1001 - $5000 Added 06/15/2020 by Robert Holladay, source=Web Response, value=Grant/Research Support No relevant relationships by Rusella Mirza, source=Web Response No relevant relationships by Derek Rainwater, source=Web Response

MEDIASTINAL LYMPHADENOPATHY AS METASTATIC MANIFESTATION OF RENAL CELL CARCINOMA

SESSION TITLE: Fellows Lung Cancer Posters SESSION TYPE: Fellow Case Report Posters PRESENTED ON: October 18-21, 2020 INTRODUCTION: Renal cell carcinoma (RCC) is one of the common malignancies diagnosed in United States.(1) Since early 1990s, its incidence has risen and thought to be attributed to the increased prevalence of risk factors such as smoking, obesity and hypertension.(2) With the advent and frequent utilization of imaging such as ultrasonography and computed tomography (CT), mortality related to RCC has declined.(1) Lung is a common site for metastatic dissemination due to invasiveness of RCC into nearby vascular structures. We present an unusual case of RCC with lymphatic metastasis to lungs, contrary to the known mechanism of vascular metastasis. CASE PRESENTATION: 57-year-old female, current smoker of 25 pack years, presents to the hospital with complaints of recurrent painful hematuria after failing outpatient management for presumed nephrolithiasis. CT abdomen showed a 9.7 cm mass in superior pole of left kidney with involvement of the adjacent adrenal gland. A subsequent chest CT showed a 1.1 cm right lower lobe sub-pleural nodule, 1.1 cm right paratracheal lymphadenopathy, and 1.47 cm subcarinal lymphadenopathy (Figure 1). Patient underwent endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsy of station 11R with pathology consistent with renal cell carcinoma. Patient was referred for nephrectomy followed by oncologic evaluation for further management with chemotherapeutic and possible immunological therapy. DISCUSSION: The incidence of pulmonary metastasis in RCC is approximately 50-60%.(3) Although commonly presenting as solitary or multiple nodules, pleural, lymphatics, or embolic phenomenon have been reported.(3) Interestingly, RCC can present with hilar or mediastinal lymphadenopathy. In cases where extensive pulmonary metastasis is present, RCC can be discovered during EBUS-TBNA, as noted in our case. (5) In our case, patient had positive lymph node for malignancy associated with the sub-pleural based nodule. It is possible that the lymphadenopathy was an indirect seeding after metastasis to right lower lobe nodule, or direct seeding into mediastinal and hilar lymph nodes. The presence of the right lower lobe nodule makes direct lymph node seeding less likely. CONCLUSIONS: In patients who present with hematuria with incidental findings of lymphadenopathy, it is worth considering RCC as a plausible diagnosis due to various pulmonary manifestations related to RCC. Reference #1: Chow, W., Dong, L., and Devesa, S. (2010). Epidemiology and risk factors for kidney cancer. Nature Reviews Urology. 2010; 7(5): 245-257. Kabaria, T., Klaassen, Z., and Terris, M. (2016). Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis. 2016; 9: 45-52. Reference #2: Motzer, R., Bander, N., and Nanus, D. (1996). Renal-cell carcinoma. N Engl J Med 1996. 335(12): 865-875. Agarwal, A., Sahni, S., Iftikhar, A., and Talwar, S. (2015). Pulmonary manifestations of renal cell carcinoma. Respiratory Medicine 109: 1505-1508. Reference #3: Val-Bernal, J., Martino, M., Romay, F., and Yllera, E. (2018). Endobrnchial ultrasound-guided transbronchial needle aspiration in the diagnosis of mediastinal metastases of clear cell renal cell carcinoma. Pathology Research and Practice. 2018; vol 214 (7): 949-956. DISCLOSURES: No relevant relationships by Kushagra Gupta, source=Web Response No relevant relationships by Anthony Loschner, source=Web Response No relevant relationships by Elizabeth McCaskey, source=Web Response No relevant relationships by Toribiong Uchel, source=Web Response

The significance of multidisciplinary classifications based on transbronchial pathology in possible idiopathic interstitial pneumonias.

Surgical lung biopsy is regarded as the golden standard for the diagnosis of idiopathic interstitial pneumonias (IIPs). Here, we attempted to show the diagnostic accuracy of multidisciplinary classifications based on transbronchial pathology including transbronchial lung cryobiopsy (TBLC) , bronchoalveolar lavage fluid (BALF) and endobronchial ultrasound-guided transbronchial needle aspiration biopsy (EBUS-TBNA).Patients with suspected interstitial lung diseases admitted from June 1, 2016 to December 31, 2018 were involved. Patients with known causes of interstitial lung diseases and typical idiopathic pulmonary fibrosis diagnosed through clinical, radiological information were excluded. Patients with atypical idiopathic pulmonary fibrosis and possible IIPs accepted transbronchial pathological evaluation. Initial multidisciplinary diagnosis (MDD) classifications were made depending on clinical, radiological and transbronchial pathological information by a multidisciplinary team (MDT). The final MDD classifications were confirmed by subsequent therapeutic effects. All patients were followed up for at least 6 months.A total of 70 patients were finally involved. The samples of lung parenchyma extracted through TBLC were enough for confirmation of pathological diagnoses in 68.6% (48/70) cases. Samples of 6 cases were extracted by EBUS-TBNA. Bacteriological diagnoses were positive in 1 case by BALF. Pathological diagnoses of 77.1% (54/70) cases were achieved through TBLC, EBUS-TBNA and BALF. During the follow up study, the pulmonary lesions of 60% patients were improved, 11.43% were relapsed when glucocorticoid was reduced to small dose or withdrawal, 14.29% were leveled off and 8.57% were progressed. The diagnoses of 4 patients with progressed clinical feature were revised. As a result, 94.3% initial MDD classifications based on transbronchial pathology were consistent with the final MDD, and the difference of diagnostic yield wasn’t significant between initial and final MDD (Z = −1.414, P = .157).Classifications of IIPs based on transbronchial pathology were useful and quite agreed with final MDD.

Diagnostic Value of Transbronchial Ultrasound-guided Needle Aspiration Biopsy in the Diagnosis of Small Cell Lung Cancer and Non-small Cell Lung Cancer

背景与目的纤维支气管镜腔内超声引导针吸活检术（endobronchial ultrasound guided transbronchial needle aspiration, EBUS-TBNA）作为近年来发展的新技术，具有操作简单、创伤小、准确率和安全性高及可重复性等优点，已成为进行肺癌诊断和纵隔分期的新标准。由于小细胞肺癌（small cell lung cancer, SCLC）和非小细胞肺癌（non-small cell lung cancer, NSCLC）的生物学特性以及治疗方案的不同，因此，在早期能诊断并鉴别的病理类型，对于肺癌的分期、治疗及预后均有很重要意义。本文探讨EBUS-TBNA在诊断SCLC和NSCLC中的准确率及敏感性。方法回顾性分析2012年1月-2018年12月首都医科大学宣武医院胸外科进行142例经支气管内超声引导针吸活检术患者的临床资料，选取最终确诊85例SCLC和NSCLC患者，比较两组差异。结果最终经免疫组化病理明确SCLC 45例，其中经EBUS-TBNA明确诊断为SCLC 42例，诊断准确率、敏感度分别为93.3%（42/45）、100.0%（42/42）。经细胞学检查明确诊断22例，诊断准确率为48.9%（22/45）；经病理明确诊断NSCLC 40例，其中经EBUS-TBNA明确诊断为NSCLC 35例，诊断准确率、敏感度分别为87.5%（35/40）、100.0%（35/35）。经细胞学检查明确诊断11例，诊断准确率为27.5%（11/40）；EBUS-TBNA在SCLC组的诊断准确率明显高于NSCLC组，且有统计学意义（P < 0.05）。结论EBUS-TBNA用于诊断SCLC较NSCLC的准确率高。EBUS-TBNA作为微创技术，可协助SCLC早期诊断，及时治疗。